Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection (Q45724156)

15 December 2017

title

Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection (English)

1 reference

15 December 2017

7

1 reference

15 December 2017

Pia Skott

2

0 references

author name string

Qin Lizeng

1

1 reference

15 December 2017

Samer Sourial

3

1 reference

15 December 2017

Charlotta Nilsson

4

1 reference

15 December 2017

Sören Andersson S

5

1 reference

15 December 2017

Mariethe Ehnlund

6

1 reference

15 December 2017

Ewa Björling

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

15 December 2017

1 reference

15 December 2017

volume

308

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

225-232

1 reference

A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB.

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135).

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Isolation of a new human retrovirus from West African patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Immunoglobulin A responses to Puumala hantavirus

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

A three-tiered view of the role of IgA in mucosal defense

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0042-6822%2802%2900088-0

7 January 2021

10.1016/S0042-6822(02)00088-0

Identifiers

DOI

1 reference

15 December 2017

1 reference